country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-149949

Copy Link Print Information

Anticancer agent 105

Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2450987-57-0
Formel: C₂₅H₂₄KN₃O₆S
Molecular Weight:533.64

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (276 KB)

Anticancer agent 105 Chemical Structure

CAS. Nr.: 2450987-57-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	3.8 μM Compound: 9cb	Cytotoxicity against mouse 4T1 cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis Cytotoxicity against mouse 4T1 cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis	[PMID: 37084598]
B16-F10	IC₅₀	2.41 μM Compound: 9cb	Cytotoxicity against mouse B16-F10 cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis Cytotoxicity against mouse B16-F10 cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis	[PMID: 37084598]
CT26	IC₅₀	4.3 μM Compound: 9cb	Cytotoxicity against mouse CT26 cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis Cytotoxicity against mouse CT26 cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis	[PMID: 37084598]
MEF	IC₅₀	>100 μM Compound: 9cb	Cytotoxicity against NF2-deficient mouse MEF cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis Cytotoxicity against NF2-deficient mouse MEF cells assessed as cell survival incubated for 24 hrs by alamarblue staining based analysis	[PMID: 37084598]

In Vitro

Anticancer agent 105 (compound 9cb) shows selectivity against cancer cells, while it inhibits survival of cancerous cells (B16–F10 melanoma) and normal non-cancerous fibroblasts (MEF NF2) with IC₅₀s of 2.41 μM, and >100 μM, respectively^[1].
Anticancer agent 105 (0.5-10 μM; 24 h) shows toxicity against cancer cells, and (5-20 μM; 48 h) induces apoptosis and necrosis in B16-F10 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

B16-F10 melanoma
Concentration:

0.5 μM, 1 μM, 5 μM, and 10 μM
Incubation Time:

24 h
Result:

Exhibited very low toxicity or were non-toxic in the case of MEF NF2 cells in the range of concentration 0.2-55 μM.

Apoptosis Analysis^[1]

Cell Line:

B16-F10 melanoma
Concentration:

5 μM, 10 μM, 15 μM, and 20 μM
Incubation Time:

48 h
Result:

Induced early apoptosis and resulted nuclear condensation.

In Vivo

Anticancer agent 105 (compound 9cb) (9-9.5 mg/kg every 3rd d for 22 d; ip) inhibits metastatic nodules in B16-F10 melanoma-bearing C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Pulmonary metastatic melanoma mouse model^[1]
Dosage:

I: 9-9.5 mg/kg; II: 42-4.6 mg/kg
Administration:

IP; once daily every 3rd d for 22 d
Result:

Decreased the number of metastatic nodules in mouse.

Chemical Information

CAS. Nr. 2450987-57-0
Molecular Weight 533.64
Formel C₂₅H₂₄KN₃O₆S
SMILES

O=C(OCC)C1=C(NC(/C(O[K])=C(C(N)=O)\C#N)=C\C(C2=CC=C(OC)C=C2)=O)SC3=C1CCCC3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rogova A, et al. Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma. Eur J Med Chem. 2023 Jun 5;254:115325. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen